11 results
SC 14D9
KNTE
Kinnate Biopharma Inc
4 Mar 24
Tender offer solicitation
5:27pm
& Benefits
Exarafenib
Other Pipeline R&D Costs
G&A Costs
Operating Expenses
Interest Income
Net Loss
Cash Adjustments
Stock-based Compensation Expense
SC14D9C
EX-99.1
KNTE
Kinnate Biopharma Inc
1 Mar 24
Written communication relating to third party tender offer
8:53am
. The company dedicated about 80% of its R&D spendings to oncology in 2022 with a focus on targeted therapies. Its current commercial portfolio
8-K
EX-99.1
KNTE
Kinnate Biopharma Inc
1 Mar 24
Entry into a Material Definitive Agreement
8:50am
. The company dedicated about 80% of its R&D spendings to oncology in 2022 with a focus on targeted therapies. Its current commercial portfolio
DEF 14A
KNTE
Kinnate Biopharma Inc
30 Apr 21
Definitive proxy
9:13am
2017, where he served as Global Head, Oncology R&D Strategy and External Innovations and Global Scientific Director, Translational Oncology. From
424B4
KNTE
Kinnate Biopharma Inc
3 Dec 20
Prospectus supplement with pricing info
4:48pm
pharmaceutical companies, and was the Global Head of Oncology R&D Strategy and External Innovations at Crown Bioscience Inc. Richard Williams, MBBS, Ph.D … was with Crown Bioscience, a translational research and pharmacology company, from January 2016 to October 2017, where he served as Global Head, Oncology R
S-1/A
n8yy2uwe
30 Nov 20
IPO registration (amended)
6:05am
S-1
vdlb2z8u5skxw5
13 Nov 20
IPO registration
5:03pm
DRS/A
0a71ct qd
3 Nov 20
Draft registration statement (amended)
12:00am
DRS/A
pp8i8o3lrf
16 Oct 20
Draft registration statement (amended)
12:00am
DRS
ip5j1u2bx4yku
4 Sep 20
Draft registration statement
12:00am
- Prev
- 1
- Next